Pandia Health’s menopause page serves two different starting points. One reader may want a clinician to assess symptoms; another may already have a prescription and want a pharmacy to receive it. Both can begin online, but they do not create the same conversation or assign the same responsibility for ongoing care.
We reviewed Pandia’s menopause service and hormone-therapy information on September 28, 2026. No consultation, transfer or payment was attempted. The assessment follows the choices a reader encounters before a visit and the questions left open afterward, including subscription qualifications that are more specific than the page’s short cancellation headlines.
Identify whether you are requesting care or fulfillment
Pandia’s menopause page provides a route for people who already hold a prescription: create an account and arrange for the prescriber or current pharmacy to send it to Pandia Pharmacy. That does not demonstrate that a Pandia clinician has assessed new symptoms or agreed to manage an existing treatment.
For a new consultation, the same page describes a health questionnaire and a doctor’s treatment proposal. Our guide to treatment goals is relevant to that assessment. The Wisp review offers another example of why clinical access and a pharmacy transaction should remain separate, even when a website makes both appear within a short online process.
Describe the problem before selecting a treatment category
The service page describes FDA-approved treatment and says it does not prescribe compounded hormones, pellets or testosterone. These statements define part of the offering; they do not determine whether hormones address a reader’s concern. The questionnaire is information for a clinician, not a way to select a medicine without evaluation.
Pandia’s hormone-therapy overview discusses several treatment forms and clinical considerations. We do not translate that educational catalog into a promise that every listed product is available through the service. A consultation can clarify the purpose of any proposed treatment, including whether a concern belongs in menopause care or needs another assessment first.
Read the payment period alongside the advertised rate
The care page displays $69 monthly, $59 per month for a three-month option, and $34.99 per month with $419.88 billed annually. These are different commitments. The annual displayed rate is not an invitation to pay $34.99 for a single month and then leave without checking the applicable terms.
The page says telehealth consultations are cash or credit rather than billed to insurance, while medication charges depend on the prescribed item and coverage. Comparing Gennev’s appointment billing makes that distinction concrete. An insurance logo on a pharmacy page does not establish that clinician access is covered, and this review did not verify a selected plan’s checkout total or benefits.
Cancellation language needs a complete reading
Pandia places cancel-anytime language near its plan offers, but further qualifications say cancellation must occur thirty days before the next billing period and that an early-cancellation fee may apply. We retain both statements. The reviewed page does not settle the amount or circumstances of every possible early fee.
That uncertainty matters before someone agrees to a longer term while still unsure whether the service suits their needs. A written explanation can distinguish ending future billing from changing clinical care or transferring a prescription. The review cannot establish that a request through customer support would be processed in time, and it does not treat ending a subscription as advice to stop a medicine.
Testing questions belong to the clinician
The FAQ on the care page says routine laboratory work is not required, while allowing testing when a particular concern needs investigation. A reader should not interpret the first part as a promise that an online questionnaire will always be enough. Nor does the possibility of testing make a self-selected panel a necessary preparation step.
Our later-start conversation guide emphasizes the history that informs an individualized discussion. The clinician can explain what information would change the decision and why. FDA menopause guidance supports weighing benefits and risks with a healthcare professional, rather than treating a symptom list, age threshold or test value as permission to start hormones.
A refill survey can surface a changed situation
Pandia describes refill reminders and requests for consent, including questions about new symptoms and medicines, on its service page. We regard that as a published communication process, not proof that each response receives immediate clinical review. A refill reminder and a scheduled discussion have different purposes.
Our bleeding-history guide explains why some changes deserve a direct clinical conversation instead of being treated as ordinary renewal information. The useful question is who receives a concerning response and how the patient learns what happens next. The page does not verify an individual response time, pharmacy stock or a completed prescription renewal, and we did not test any of those steps.
Leave room for concerns that a broad intake can miss
The hormone overview discusses vaginal treatment separately from other hormone forms. Our vaginal-symptom visit guide helps a reader explain discomfort without assuming that a systemic medicine is the answer. The public treatment explanation should open questions, not close them before the appointment.
Pandia’s most useful distinction is between obtaining new clinical advice and arranging fulfillment of advice already given elsewhere. A complete handoff identifies which clinician remains responsible, what follow-up is expected and what the patient should do when an issue cannot be resolved through the current channel. Those answers depend on the actual care arrangement, not merely on which online enrollment button was selected.
Read alongside the article
Sources & notes.
These sources provide provider descriptions or medical context. They do not replace an individual clinical assessment.
- Pandia Health: menopause care and pharmacy service ↗Provider membership and pharmacy page; drug costs excluded, savings captions and cancellation qualifications retained · Checked 2026-09-28
- Pandia Health: menopause hormone-therapy explanation ↗Provider treatment explanation; educational categories do not establish every item as a supplied US offering · Checked 2026-09-28
- FDA: Menopause ↗Current federal patient guidance; individualized benefits/risks and prevention limits, no class-wide labeling-change inference · Checked 2026-09-28